First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study
4 affiliations
- 1Liver Unit, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
- 2I Medical Department, University Medical Center, Mainz, Germany
- 3Division of Medical Oncology, National Cancer Centre, Singapore
- 4Centre of Cancer Medicine and University Department of Medicine, The University of Hong Kong, Hong Kong, China
Abstract
In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the primary safety and efficacy data from CheckMate 9DW as well as key sub-group analyses and additional findings. The third part focuses on the early crossing phenomenon of the overall survival Kaplan–Meier (KM) curves and discussion of potential contributors. The fourth part discusses the management of adverse events, the timing of immune‑mediated adverse events, and the impact of discontinuation and steroid use on efficacy. Across all parts, implications for clinical practice will be discussed, including topics such as patient selection, sequencing of therapies, immune-mediated toxicities, monitoring recommendations, and real-world considerations.
Related
- Enhanced Efficacy of Thalidomide‐Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi‐Center Cohort Study
- Survival outcomes of spleen-strengthening and dampness-eliminating traditional Chinese medicine granules combined with lenvatinib for unresectable hepatocellular carcinoma: a large-sample retrospective study based on electronic medical records
- Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
BibTeX
@article{sangro2026firstline,
title = {{First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study}},
author = {Bruno Sangro and Peter Galle and David Tai and Thomas Yau},
journal = {Future Oncology},
year = {2026},
month = sep,
doi = {10.1080/14796694.2026.2726118},
url = {https://doi.org/10.1080/14796694.2026.2726118},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study
AU - Bruno Sangro
AU - Peter Galle
AU - David Tai
AU - Thomas Yau
PY - 2026
DA - 2026/09/22
JO - Future Oncology
DO - 10.1080/14796694.2026.2726118
UR - https://doi.org/10.1080/14796694.2026.2726118
AB - In this podcast, over a series of four parts, the authors provide an overview of the CheckMate 9DW study (NCT04039607) in hepatocellular carcinoma (HCC) and their opinions on how it impacts the treatment landscape for first-line unresectable HCC. The first two parts provide an overview of the primary safety and efficacy data from CheckMate 9DW as well as key sub-group analyses and additional findings. The third part focuses on the early crossing phenomenon of the overall survival Kaplan–Meier (KM) curves and discussion of potential contributors. The fourth part discusses the management of adverse events, the timing of immune‑mediated adverse events, and the impact of discontinuation and steroid use on efficacy. Across all parts, implications for clinical practice will be discussed, including topics such as patient selection, sequencing of therapies, immune-mediated toxicities, monitoring recommendations, and real-world considerations.
SN - 1479-6694
SN - 1744-8301
ER -